Get the Stockscreener App
683.08
0.67%
-4.19
After Hours:
683.08
Regeneron Pharmaceuticals Inc stock is traded at $683.08, with a volume of 743.07K.
It is down -0.67% in the last 24 hours and down -2.83% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$687.27
Open:
$688.31
24h Volume:
743.07K
Relative Volume:
0.91
Market Cap:
$74.97B
Revenue:
$13.85B
Net Income/Loss:
$4.65B
P/E Ratio:
16.90
EPS:
40.41
Net Cash Flow:
$3.32B
1W Performance:
-1.72%
1M Performance:
-2.83%
6M Performance:
-36.66%
1Y Performance:
-28.87%
1-Day Range:
$674.33
$689.62
1-Week Range:
$674.33
$698.45
52-Week Range:
$666.25
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Wolfe Research Cuts Regeneron Pharmaceuticals Price Target to $1,000 From $1,150 - Marketscreener.com
CAFC Applies Minimum Contacts Analysis of Acorda to Infringement Case Over Eylea Biosimilar - IPWatchdog.com
Join Lee Rennick at the CIO100 with Bob McCowan, SVP & CIO, Regeneron, on CIO Leadership Live - CIO
Leerink Partnrs Issues Positive Forecast for REGN Earnings - MarketBeat
Robeco Institutional Asset Management B.V. Purchases 1,130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Forsta AP Fonden - MarketBeat
SteelPeak Wealth LLC Has $2.01 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
Kingswood Wealth Advisors LLC Sells 1,431 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What is Leerink Partnrs’ Forecast for REGN FY2024 Earnings? - Defense World
Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise - MSN
Fed. Circ. Affirms Delaying Biosimilars For Regeneron's Eylea - Law360
Federal Circuit Affirms Injunctions on Eylea Biosimilar Sales - Bloomberg Law
Federal Court delists Regeneron patent, clearing path for Amgen biosimilar launch - Law360 Canada
Biologics Patent Enforcement: Regeneron Patents Block Biosimilar Entry for EYLEA - Patently-O
REGN INVESTOR NOTICE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - GlobeNewswire Inc.
Fibrodysplasia Ossificans Progressiva Market Set to Grow - openPR
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $903 From $950, Keeps Outperform Rating - Marketscreener.com
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,030 From $1,230, Keeps Buy Rating - Marketscreener.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
R Squared Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Perigon Wealth Management LLC - MarketBeat
FY2024 Earnings Forecast for REGN Issued By Leerink Partnrs - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Pacer Advisors Inc. - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure - The Bakersfield Californian
REGENERON ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy - EIN News
Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline - Yahoo Finance
Is Regeneron Pharmaceuticals Set to Rebound? The Future Looks Promising! - Zaman
Tamar Securities LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Leerink cuts Regeneron stock price target to $762 from $880 - MSN
Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options - Yahoo Finance
Is Regeneron Pharmaceuticals (REGN) Among the Best Depressed Stocks to Invest in Now? - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $750.00 Price Target at Citigroup - MarketBeat
Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock - Benzinga
Leerink Partners Adjusts Regeneron Pharmaceuticals Price Target to $762 From $880, Maintains Market Perform Rating - Marketscreener.com
Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $795, Maintains Neutral Rating - Marketscreener.com
Slow Capital Inc. Buys 410 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action La - GuruFocus.com
Regeneron Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsREGN - Morningstar
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,013.00 by Analysts at Piper Sandler - Defense World
Regeneron's SWOT analysis: biotech giant's stock faces challenges, opportunities - Investing.com
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - Marketscreener.com
Is Regeneron Pharmaceuticals (REGN) the Best Stock to Buy and Hold for 2025? - Insider Monkey
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.64%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):